NCT06321913View on ClinicalTrials.gov

Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Interventions
DRUG

IBI343 combined with IBI308

IBI343 Specifications: 100 mg/bottle Approval method: TBD Q3W intravenous infusion (IV) sintilimab Specifications: 100mg (10ml)/bottle Afghan way: 200 mg Q3W IV infusion

All Listed Sponsors
collaborator

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

lead

Harbin Medical University

OTHER

NCT06321913 - Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | Biotech Hunter | Biotech Hunter